Evidence map›Paper›PMID 31594549›Full record

ArticleActa neuropathologica communications2019

Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers.

Dennis W Dickson, Matthew C Baker, Jazmyne L Jackson, Mariely DeJesus-Hernandez, NiCole A Finch, Shulan Tian, Michael G Heckman, Cyril Pottier, Tania F Gendron, Melissa E Murray and 13 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 56 citations in OpenAlex.

  1. International journal of molecular sciences · 2021
    Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Frontiers in neuroscience · 2024
    Article
  16. Article
  17. Cells · 2023
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Matthew C BakerDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Jazmyne L JacksonDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Mariely DeJesus-HernandezDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
NiCole A FinchDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Shulan TianDepartment of Health Sciences Research, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.
Michael G HeckmanDivision of Biomedical Statistics and Informatics, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Cyril PottierDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Tania F GendronDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Yingxue RenDepartment of Health Sciences Research, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Joseph S ReddyDepartment of Health Sciences Research, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.
Leonard PetrucelliDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Björn OskarssonDepartment of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
John W SheppardGianforte School of Computing, Montana State University, 357 Barnard Hall, Bozeman, MT, 59717, USA.
Yan W AsmannDepartment of Health Sciences Research, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Rosa RademakersDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. Rademakers.Rosa@mayo.edu.
Marka van BlitterswijkDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. VanBlitterswijk.Marka@mayo.edu.
Mayo Clinic in Florida · USMayo Clinic · USMontana State University · US

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI Bradley F Boeve · 2019 to 2026
$120.9M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5M
Project 3: Neuropathology of the multi-proteinopathy of c9FTD/ALS.P01NS084974 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2014 to 2024
$17.6M
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)U01AG045390 · NIA · MAYO CLINIC ROCHESTER · PI BOEVE, BRADLEY F, ROSEN, HOWARD J · 2014 to 2018
$16.9M
Expanding insights into FTD disease mechanismsR35NS097273 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2017 to 2024
$10.6M
Training - The Frontotemporal Lobar Degeneration Clinical Research ConsortiumU54NS092089 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2014 to 2018
$6.4M
Genetic Discovery and Pathobiology of Frontotemporal Lobar Degeneration and Related TDP-43 ProteinopathiesR35NS097261 · NINDS · MAYO CLINIC JACKSONVILLE · PI RADEMAKERS, ROSA · 2017 to 2019
$2.9M
Uncovering RNA signatures of C9ORF72-linked ALS and related disordersR21NS110994 · NINDS · MAYO CLINIC JACKSONVILLE · PI VAN BLITTERSWIJK, MARKA · 2019 to 2019
$430k
C9ORF72 levels: implications for diagnosis, prognosis, and treatment of ALS and related disordersR21NS099631 · NINDS · MAYO CLINIC JACKSONVILLE · PI VAN BLITTERSWIJK, MARKA · 2017 to 2018
$430k
NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062677NIA NIH HHS P50 AG016574NIA NIH HHS U01 AG045390NIA NIH HHS U19 AG063911NINDS NIH HHS P01 NS084974NINDS NIH HHS R21 NS099631NINDS NIH HHS R21 NS110994NINDS NIH HHS R35 NS097261NINDS NIH HHS R35 NS097273NINDS NIH HHS U54 NS092089
6 · The paper itself

Abstract

The majority of the clinico-pathological variability observed in patients harboring a repeat expansion in the C9orf72-SMCR8 complex subunit (C9orf72) remains unexplained. This expansion, which represents the most common genetic cause of frontotemporal lobar degeneration (FTLD) and motor neuron disease (MND), results in a loss of C9orf72 expression and the generation of RNA foci and dipeptide repeat (DPR) proteins. The C9orf72 protein itself plays a role in vesicular transport, serving as a guanine nucleotide exchange factor that regulates GTPases. To further elucidate the mechanisms underlying C9orf72-related diseases and to identify potential disease modifiers, we performed an extensive RNA sequencing study. We included individuals for whom frontal cortex tissue was available: FTLD and FTLD/MND patients with (n = 34) or without (n = 44) an expanded C9orf72 repeat as well as control subjects (n = 24). In total, 6706 genes were differentially expressed between these groups (false discovery rate [FDR] < 0.05). The top gene was C9orf72 (FDR = 1.41E-14), which was roughly two-fold lower in C9orf72 expansion carriers than in (disease) controls. Co-expression analysis revealed groups of correlated genes (modules) that were enriched for processes such as protein folding, RNA splicing, synaptic signaling, metabolism, and Golgi vesicle transport. Within our cohort of C9orf72 expansion carriers, machine learning uncovered interesting candidates associated with clinico-pathological features, including age at onset (vascular endothelial growth factor A [VEGFA]), C9orf72 expansion size (cyclin dependent kinase like 1 [CDKL1]), DPR protein levels (eukaryotic elongation factor 2 kinase [EEF2K]), and survival after onset (small G protein signaling modulator 3 [SGSM3]). Given the fact that we detected a module involved in vesicular transport in addition to a GTPase activator (SGSM3) as a potential modifier, our findings seem to suggest that the presence of a C9orf72 repeat expansion might hamper vesicular transport and that genes affecting this process may modify the phenotype of C9orf72-linked diseases.

Indexed as

HeterozygoteAgedAged, 80 and overC9orf72 ProteinDNA Repeat ExpansionFemaleFrontal LobeGene Regulatory NetworksHumansMaleMiddle AgedProtein TransportTranscriptomeC9orf72 ProteinC9orf72 protein, humanAmyotrophic lateral sclerosisC9orf72Frontotemporal dementiaFrontotemporal lobar degenerationMachine learningMotor neuron diseaseRepeat expansion disordersRNA sequencingTranscriptomicsVesicular transport

Identifiers

PMID31594549
PMCPMC6781370
OpenAlexW2979518663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.